Why Adaptimmune Therapeutics Was Sinking This Week
In an about-face from its impressive performance last week, Adaptimmune Therapeutics (NASDAQ: ADAP) stock declined by nearly 14% over the past five trading days. This occurred even though the cancer-focused biotech actually divulged some good news.
That news was certainly encouraging. On Monday, Adaptimmune said that its phase 1 SURPASS trial gauging the efficacy of its ADP-A2M4CD8 SPEAR T-cell therapy to reduce certain types of solid tumors showed a response rate of 36% and a disease control rate of 86%. One patient with ovarian cancer recorded a complete response to the therapy.
Image source: Getty Images.
Source Fool.com
